Fascioliasis, caused by the liver fluke Fasciola hepatica, poses significant health challenges worldwide. This parasitic disease often leads to liver damage and biliary complications. The need for effective treatment strategies is paramount. Among potential options, atovaquone has emerged as a promising candidate. Understanding its pharmacokinetics and clinical implications is essential for optimizing treatment outcomes. Atovaquone […]
